Cargando…

Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?

BACKGROUND: Switching to aripiprazole from other antipsychotics can avoid antipsychotic-induced hyperprolactinemia but may result in an abnormally low prolactin level. This study aimed to assess whether the aripiprazole-induced abnormally low prolactin level was a biomarker for subsequent rebound of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jen, Ya-Wen, Hwang, Tzung-Jeng, Chan, Hung-Yu, Hsieh, Ming H., Liu, Chen-Chung, Liu, Chih-Min, Hwu, Hai-Gwo, Kuo, Ching-Hua, Lin, Yi-Ting, Chien, Yi-Ling, Chen, Wei J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686669/ https://www.ncbi.nlm.nih.gov/pubmed/33228575 http://dx.doi.org/10.1186/s12888-020-02957-7

Ejemplares similares

Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia
por: Ma, Chia-Hao, et al.
Publicado: (2022)

PM390. Comparison of Fast Versus Slow Strategy in Switching Schizophrenia Patients to Aripiprazole from Other Antipsychotics
por: Hwang, Tzung-Jeng, et al.
Publicado: (2016)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia
por: Tseng, Huai-Hsuan, et al.
Publicado: (2013)

T182. SHARED AND DISTINCT ALTERATIONS IN THE WHITE MATTER TRACTS OF REMITTED AND NON-REMITTED PATIENTS WITH SCHIZOPHRENIA
por: Hwang, Tzung-Jeng, et al.
Publicado: (2018)

Frequency Dependent Alterations in Regional Homogeneity of Baseline Brain Activity in Schizophrenia
por: Yu, Rongjun, et al.
Publicado: (2013)

Differentiation of Schizophrenia Patients from Healthy Subjects by Mismatch Negativity and Neuropsychological Tests
por: Lin, Yi-Ting, et al.
Publicado: (2012)

A Diagnostic Model Incorporating P50 Sensory Gating and Neuropsychological Tests for Schizophrenia
por: Shan, Jia-Chi, et al.
Publicado: (2013)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021)

Hemispheric lateralization of semantic processing before and after aripiprazole treatment in first-episode psychosis or ultra-high risk state
por: Hwang, Tzung-Jeng, et al.
Publicado: (2022)

Auditory Event-Related Potentials in Antipsychotic-Free Subjects With Ultra-High-Risk State and First-Episode Psychosis
por: Hsieh, Ming H., et al.
Publicado: (2019)

S122. TEN-YEAR FOLLOW-UP AFTER FIRST EPISODE PSYCHOSIS: FOCUSED ON LOW DOSE ANTIPSYCHOTIC MAINTENANCE AND FUNCTIONING
por: Liu, Chen-Chung, et al.
Publicado: (2020)

Challenging the Minimum Effective Antipsychotic Dose During Maintenance: Implications From 10-Year Follow-Up of First Episode Psychosis
por: Liu, Chen-Chung, et al.
Publicado: (2021)

Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose
por: Liu, Chen-Chung, et al.
Publicado: (2023)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
por: Zhi, Pu, et al.
Publicado: (2018)

Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship
por: Yu, Ya-Hui, et al.
Publicado: (2022)

Detection of advanced brain aging in schizophrenia and its structural underpinning by using normative brain age metrics
por: Chen, Chang-Le, et al.
Publicado: (2022)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

S139. PROGRESSIVE DETERIORATION OF WHITE MATTER TRACTS IN SCHIZOPHRENIA: A DIFFUSION MRI STUDY ON A LARGE SINGLE COHORT USING NORMATIVE MODELS
por: Hwang, Tzung-Jeng, et al.
Publicado: (2020)

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
por: Kane, John M., et al.
Publicado: (2015)

Misattributing the Source of Self-Generated Representations Related to Dissociative and Psychotic Symptoms
por: Chiu, Chui-De, et al.
Publicado: (2016)

Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists’ Attitudes in Taiwan
por: Yen, Ko, et al.
Publicado: (2022)

Arcuate Fasciculus Abnormalities and Their Relationship with Psychotic Symptoms in Schizophrenia
por: Abdul-Rahman, Muhammad Farid, et al.
Publicado: (2012)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
por: Tien, Yun, et al.
Publicado: (2022)

Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia
por: Zhou, Zhenhe, et al.
Publicado: (2013)

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
por: Kelly, Deanna L, et al.
Publicado: (2013)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2009)

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis
por: Fountoulakis, Konstantinos N, et al.
Publicado: (2010)

Dual-modality impairment of implicit learning of letter-strings versus color-patterns in patients with schizophrenia
por: Chiu, Ming-Jang, et al.
Publicado: (2005)

Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia
por: Barak, Yoram, et al.
Publicado: (2011)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases
por: Muneoka, Katsumasa, et al.
Publicado: (2017)

Impaired Flush Response to Niacin Skin Patch Among Schizophrenia Patients and Their Nonpsychotic Relatives: The Effect of Genetic Loading
por: Chang, Shu-Sen, et al.
Publicado: (2009)

Aripiprazole: the evidence of its therapeutic impact in schizophrenia
por: Winlow, William, et al.
Publicado: (2006)

Aripiprazole-associated tic in a schizophrenia patient
por: Guo, Xieli, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t2jv6p51d10aucom22v85tp30t